Health
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic arthritis","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Data includes real-world evidence of minimal disease activity and clinical long-term safety outcomes of upadacitinib in atopic dermatitis, as well as investigational Phase 3 data for vitiligo and alopecia areata ","length":211,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":372,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., March 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.","length":248,"tagName":"p"},{"type":"text","content":"AbbVie will present 24 abstracts at AAD, including one late-breaking presentation, with key data reinforcing the company's leadership in advancing standards of care across immune-mediated skin diseases. This robust clinical evidence, spanning a wide range of dermatologic diseases, demonstrates durable and sustained treatment responses, long-term safety and improvements in quality of life, in addition to real-world evidence that reinforce disease control.","length":462,"tagName":"p"},{"type":"text","content":""Through our data at AAD, AbbVie reinforces the importance of sustained efficacy and safety to re-shape standards of care and ultimately inform future treatment paradigms that can be transformative for people living with immune-mediated skin diseases," said Andrew Anisfeld, Ph.D., vice president, global medical affairs, immunology, AbbVie. "Our robust evidence across multiple clinical trials and real-world data sources for risankizumab and upadacitinib reaffirm AbbVie's dedication to supporting improved patient outcomes."","length":551,"tagName":"p"},{"type":"text","content":"Long-term Outcomes in Psoriatic Arthritis and Atopic Dermatitis","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Maintenance of radiographic nonprogression outcomes in psoriatic arthritis: An analysis reviewing the long-term (five-year) efficacy and radiographic outcomes of risankizumab from the KEEPsAKE-1 Ph...